Flagstar Bank NA vs Mesoblast Limited — how do they compare? Flagstar Bank NA trades at $11.36 (market cap $4.71B), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: Flagstar Bank NA is far larger — about 2.7× Mesoblast Limited's market cap, and Flagstar Bank NA pays a 0.35% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Flagstar Bank NA for 21 Days and Mesoblast Limited for 14 Days on average.
| FLG | MESO | |
|---|---|---|
Market Cap | $4.71B | $1.75B |
Volume | 7,410,589 | 239,027 |
Sector | Financials | Health |
52-Week High | $15.36 | $20.96 |
52-Week Low | $10.72 | $13.19 |
Typical Hold Time | 21 Days | 14 Days |
Enterprise Value | $15.25B | $1.83B |
Dividend Yield | 0.35% | — |
Signals from Pluang's Aura AI — not financial advice
Flagstar Bank (FLG) trades at $11.30, down 2.25% on the day, with a bearish technical outlook despite recent earnings beats. The company shows improving fundamentals with Q2 2026 marking the third consecutive profitable quarter, though it missed EPS estimates. Analyst sentiment remains positive with a $17.07 consensus price target representing 51% upside potential. Recent strategic developments include a $250 million share repurchase program and a new core banking partnership with Fiserv.
The stock presents a compelling value opportunity trading at 0.62x book value, but faces risks from volatile earnings performance and negative cash flow trends. While analyst consensus is bullish with 60% buy ratings, investors should monitor execution on profitability improvements and the impact of recent strategic initiatives on long-term growth.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Trailing returns across standard periods
Latest headlines on both assets
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →